Exact Sciences Corp. reported that its Cologuard test, deployed through a partnership with Privia Health and Amalgam Rx, achieved an 84% colorectal cancer screening rate among eligible patients aged 45 and older in 2024. The rate exceeds the National Colorectal Cancer Roundtable’s 80% target and represents a 5‑percentage‑point increase over the 79% rate recorded in 2023 for the same program.
The program, which began in 2023 and expanded nationwide in 2024, leveraged Amalgam Rx’s medical‑grade AI to identify eligible patients and automate outreach, while Privia Health’s integration with athenaClinicals® embedded ordering and results delivery directly into the EHR. The combination of AI‑driven decision support and seamless EHR workflow enabled the high screening uptake.
The 84% figure underscores Exact Sciences’ ability to scale its stool‑based DNA test through digital workflows, reinforcing its competitive advantage over FIT and blood‑based alternatives. The milestone also positions the company to capture a larger share of the estimated $25 billion colorectal cancer screening market.
While the original article claimed a 40% increase over the previous year’s rate, the fact‑check confirms the increase was 5 percentage points, reflecting a modest year‑over‑year improvement in the program’s reach. The program’s success demonstrates the effectiveness of integrated technology and partnership models in driving preventive care.
Exact Sciences is also in the final stages of a pending merger with Abbott, with a shareholder vote scheduled for February 20 2026 and a targeted close in Q2 2026. The screening program’s success adds momentum to the company’s broader strategy of expanding its diagnostic portfolio and strengthening its market position ahead of the acquisition.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.